BioCryst Pharmaceuticals is trading 5.5% up at $10.27 in after-hours trading, rebounding from recent declines as the company sees renewed analyst focus.
- JPMorgan resumed coverage of the stock with a Neutral rating and a $12.00 price target, highlighting the company's rare-disease strategy.
- Other firms maintain bullish commentary regarding the firm's hereditary angioedema (HAE) portfolio, which remains a primary growth driver.
- While broader indices are trading modestly higher, the specific analyst activity is the main catalyst for the current price action.